Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Analyst Outlook Dims for Exelon Shares

Felix Baarz by Felix Baarz
October 25, 2025
in Analysis, Earnings, Energy & Oil
0
Exelon Stock
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

Exelon faces mounting pressure from market analysts as downward revisions to earnings forecasts and cautious institutional sentiment weigh on the utility stock. Recent developments have created headwinds for the company’s share performance ahead of its upcoming quarterly report.

Earnings Estimates Adjusted

Financial research firm Zacks Research revised its earnings outlook for Exelon downward last Friday. The firm now anticipates full-year 2025 earnings of $2.65 per share, a slight reduction from its previous projection of $2.67. This updated forecast places Zacks just marginally above the consensus estimate of $2.64 per share among market analysts.

Institutional Skepticism Persists

Morgan Stanley maintained its “Equal-Weight” rating on Exelon shares, signaling continued caution toward the utility company. This positioning reflects the investment bank’s restrained outlook for the stock’s near-term performance.

Market activity reflected this tempered sentiment, with Exelon shares declining 1.06 percent to close at $47.60 on Thursday. The downward trend continued through Friday’s trading session, extending the stock’s recent weakness.

Should investors sell immediately? Or is it worth buying Exelon?

Quarterly Performance Provides Mixed Signals

While Exelon surpassed earnings expectations in the second quarter with $0.39 per share—$0.02 above analyst predictions—the company reported revenue of $5.43 billion that fell short of market expectations. Despite this mixed performance, management reaffirmed their full-year guidance range of $2.64 to $2.74 per share.

Looking further ahead, analysts have established quarterly projections for future periods:
* Q4 2025 Forecast: $0.65 EPS
* Q2 2026 Forecast: $0.43 EPS
* Q3 2026 Forecast: $0.75 EPS

Technical Position and Upcoming Catalyst

Exelon shares are currently trading around their 50-day moving average of $44.89, remaining substantially below the 52-week high of $48.51. The stock’s performance suggests investors are awaiting clearer signals about the company’s ability to meet its annual targets.

All eyes now turn to November 4th, when Exelon will report third-quarter 2025 results. This announcement represents a critical test for the company to demonstrate its capacity to counter the recent downward revisions to earnings projections and restore investor confidence.

Ad

Exelon Stock: Buy or Sell?! New Exelon Analysis from February 7 delivers the answer:

The latest Exelon figures speak for themselves: Urgent action needed for Exelon investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Exelon: Buy or sell? Read more here...

Tags: Exelon
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
IAC/InterActiveCorp Stock

Mixed Signals for IAC Stock as Conflicting Trends Emerge

iShares MSCI World ETF Stock

MSCI World ETF Rides AI Wave to Impressive Returns

Crane Company Stock

Crane Company Faces Pivotal Week with Q3 Earnings Release

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com